According to the U.S. Centers for Disease Control and Prevention (CDC) and other sources, there are approximately 1.2 million people living with HIV in the United States, and another 1.2 to 2.2 million who are at highest risk for infection and could benefit from the preventive measure known as HIV pre-exposure prophylaxis (PrEP).
Important FDA-approved drugs to treat HIV and cancer can save lives, but they come with their own risks. Some drugs used clinically are known to cause neurological side effects in up to half of patients, ranging from confusion and memory problems to permanent nerve damage.
The World Health Organization (WHO) has validated Brazil for the elimination of mother-to-child transmission (EMTCT) of HIV, making it the most populous country in the Americas to achieve this historic milestone.
Advancements in HIV/AIDS research, drug development and clinical practice since the 1980s have made it possible for people living with HIV to lead long, productive lives and keep the virus in check at undetectable levels and nontransmissible as long as therapy is maintained.
Why did you receive this email?
You are receiving this email because you subscribed to updates from AZoNetwork UK Ltd. on one of
our websites
and requested to be notified of additional information.
